Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1426916-02-0

C22H23F3N4O2, also known as ML-298, is a potent and specific inhibitor of Phospholipase D2 (PLD2) with an IC50 value of 355 nM. It selectively targets PLD2 over PLD1, showing a significant difference in its inhibitory effect on the two isoforms. ML-298 has been found to decrease the invasive migration of U87-MG glioblastoma cells at a concentration of 10 μM without causing cytotoxicity.

1426916-02-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1426916-02-0 Structure

  • Basic information

    1. Product Name: C22H23F3N4O2
    2. Synonyms:
    3. CAS NO:1426916-02-0
    4. Molecular Formula:
    5. Molecular Weight: 432.445
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1426916-02-0.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C22H23F3N4O2(CAS DataBase Reference)
    10. NIST Chemistry Reference: C22H23F3N4O2(1426916-02-0)
    11. EPA Substance Registry System: C22H23F3N4O2(1426916-02-0)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1426916-02-0(Hazardous Substances Data)

1426916-02-0 Usage

Uses

1. Used in Pharmaceutical Industry:
C22H23F3N4O2 is used as a research compound for studying the role of PLD2 in various cellular processes and its potential as a therapeutic target in cancer and other diseases.
2. Used in Cancer Research:
C22H23F3N4O2 is used as an inhibitor of PLD2 to investigate its effects on the invasive migration of glioblastoma cells, a type of aggressive brain cancer. By inhibiting PLD2, ML-298 may help in understanding the underlying mechanisms of cancer progression and the development of novel therapeutic strategies.
3. Used in Drug Development:
C22H23F3N4O2 is used as a lead compound in the development of new drugs targeting PLD2, which may have potential applications in treating various diseases, including cancer.
4. Used in Cell Biology Research:
C22H23F3N4O2 is used as a tool to study the function of PLD2 in cellular processes, such as cell migration, invasion, and signaling pathways, which are crucial for understanding the molecular basis of various diseases.
5. Used in Biochemical Assays:
C22H23F3N4O2 is used as a specific inhibitor of PLD2 in biochemical assays to measure the enzyme's activity and its role in different cellular processes.

Biochem/physiol Actions

ML298 is a potent, specific inhibitor of Phospholipase D2 (PLD2; IC50 = 355 nM). ML298 does not affect PLD1 activity at concentrations up to 20 μM.

Check Digit Verification of cas no

The CAS Registry Mumber 1426916-02-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,6,9,1 and 6 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1426916-02:
(9*1)+(8*4)+(7*2)+(6*6)+(5*9)+(4*1)+(3*6)+(2*0)+(1*2)=160
160 % 10 = 0
So 1426916-02-0 is a valid CAS Registry Number.

1426916-02-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail

  • Sigma

  • (SML1077)  ML298  ≥98% (HPLC)

  • 1426916-02-0

  • SML1077-5MG

  • 1,026.09CNY

  • Detail

  • Sigma

  • (SML1077)  ML298  ≥98% (HPLC)

  • 1426916-02-0

  • SML1077-25MG

  • 4,144.14CNY

  • Detail

1426916-02-0Downstream Products

1426916-02-0Relevant articles and documents

Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-triazaspiro[4.5]decane core: Discovery of ML298 and ML299 that decrease invasive migration in U87-MG glioblastoma cells

O'Reilly, Matthew C.,Scott, Sarah A.,Brown, Kyle A.,Oguin, Thomas H.,Thomas, Paul G.,Daniels, J. Scott,Morrison, Ryan,Brown, H. Alex,Lindsley, Craig W.

, p. 2695 - 2699 (2013/05/22)

An iterative parallel synthesis effort identified a PLD2 selective inhibitor, ML298 (PLD1 IC50 > 20 000 nM, PLD2 IC50 = 355 nM) and a dual PLD1/2 inhibitor, ML299 (PLD1 IC50 = 6 nM, PLD2 IC50 = 20 nM). SAR studies revealed that a small structural change (incorporation of a methyl group) increased PLD1 activity within this classically PLD2-preferring core and that the effect was enantiospecific. Both probes decreased invasive migration in U87-MG glioblastoma cells.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1426916-02-0